Hememics
2 known investors
Hememics develops FAST (Functionalized Analyte Screening Technology), an immunoassay-based screening platform that lets researchers use their own antibodies and antigens to screen antibody mini-panels in under an hour. Positioned as a faster, lower-cost alternative to ELISA, it delivers digital end-point results using a 96-well plate and a compatible reader.
Founders & leadership
JL
John L. Warden, Jr.Founder & CEO, Chairman of the Board
DH
David HoFounder, President & CSO
RL
Richard LiuCFO & Board Member
Investors · 2
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $185.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Hememics do?
- Hememics develops FAST (Functionalized Analyte Screening Technology), an immunoassay-based screening platform that lets researchers use their own antibodies and antigens to screen antibody mini-panels in under an hour. Positioned as a faster, lower-cost alternative to ELISA, it delivers digital end-point results using a 96-well plate and a compatible reader.
- Who founded Hememics?
- Hememics was founded by John L. Warden, Jr., David Ho.
- Who are Hememics's investors?
- Hememics's investors include Maryland TEDCO, TEDCO.